Shaker Andrew, Jones Rowena
University of Birmingham, Birmingham, West Midlands, UK.
Birmingham and Solihull Mental Health NHS Foundation Trust, Old QE Hospital, Birmingham, B1 3RB, UK.
Ther Adv Psychopharmacol. 2018 Jan;8(1):3-11. doi: 10.1177/2045125317741449. Epub 2017 Nov 19.
Research in patients with treatment-resistant schizophrenia has demonstrated that clozapine discontinuation is associated with poor outcomes. There is, however, a paucity of research investigating the impact of clozapine discontinuation specifically in younger patients with more recent onset schizophrenia. A case note review was therefore conducted to ascertain medium-term prognoses in patients with treatment-resistant schizophrenia under an early intervention service (EIS) following clozapine discontinuation.
The case notes of 25 patients under the care of Birmingham EIS who discontinued clozapine were examined retrospectively. Reasons for discontinuation were recorded. Clinical outcomes including total duration of inpatient or home treatment admission, antipsychotic dose, number of alternative antipsychotics prescribed and adverse events were recorded for both the year before and the year after stopping clozapine. Statistical comparisons of pre- and post-discontinuation clinical outcomes determined whether discontinuation had negative effects.
There was no significant difference between the pre- and post-discontinuation clinical status following clozapine discontinuation. More than half (56%) of patients remained stable after stopping clozapine. Mean inpatient or home treatment stay rose from 29.7 to 62.6 days ( = 0.155), total antipsychotic dose from 50.1% of British National Formulary (BNF) limits to 60.5% ( = 0.627), number of alternative antipsychotics prescribed from 1.28 to 1.80 ( = 0.186), number of hospital/home treatment episodes from 0.20 to 0.44 ( = 0.083) and number of adverse events from 0 to 0.20 ( = 0.059). Non-compliance was the main reason for discontinuation (44%, = 11).
This is the first clozapine discontinuation study specifically considering EIS patients. Discontinuation did not lead to significant effects on 1 year outcomes, though the study is underpowered. These findings may be used to inform future prospective cohort discontinuation studies.
针对难治性精神分裂症患者的研究表明,停用氯氮平与不良预后相关。然而,专门研究停用氯氮平对近期发病的年轻精神分裂症患者影响的研究却很少。因此,进行了一项病例记录回顾,以确定在早期干预服务(EIS)下停用氯氮平的难治性精神分裂症患者的中期预后。
回顾性检查了伯明翰EIS所护理的25例停用氯氮平患者的病例记录。记录了停药原因。记录了停用氯氮平前一年和停药后一年的临床结局,包括住院或家庭治疗的总时长、抗精神病药物剂量、开具的替代抗精神病药物数量以及不良事件。对停药前后临床结局进行统计学比较,以确定停药是否有负面影响。
停用氯氮平后,停药前后的临床状况无显著差异。超过一半(56%)的患者在停用氯氮平后保持稳定。平均住院或家庭治疗时长从29.7天增至62.6天(P = 0.155),抗精神病药物总剂量从英国国家处方集(BNF)限量的50.1%增至60.5%(P = 0.627),开具的替代抗精神病药物数量从1.28种增至1.80种(P = 0.186),住院/家庭治疗发作次数从0.20次增至0.44次(P = 0.083),不良事件数量从0起增至0.20起(P = 0.059)。不依从是停药的主要原因(44%,n = 11)。
这是第一项专门针对EIS患者的氯氮平停药研究。尽管该研究效能不足,但停药对1年结局未产生显著影响。这些发现可用于为未来的前瞻性队列停药研究提供参考。